- Home
- KALU vs RCUS Comparison
KALU vs RCUS Comparison
Compare KALU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALU | RCUS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KALU | RCUS |
|---|---|---|
| Price | $149.33 | $23.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $168.25 | $39.91 |
| AVG Volume (30 Days) | 159.5K | ★ 1.5M |
| Earning Date | 10-21-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $1,585,900,000.00 | $247,000,000.00 |
| Revenue This Year | $42.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.46 | $14.26 |
| 52 Week High | $199.89 | $31.74 |
Technical Indicators
Market Signals| Indicator | KALU | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 34.48 |
| Support Level | $148.79 | $22.59 |
| Resistance Level | $150.00 | $24.33 |
| Average True Range (ATR) | 5.44 | 1.17 |
| MACD | 0.40 | -0.06 |
| Stochastic Oscillator | 49.45 | 15.98 |
Price Performance
Historical ComparisonAbout KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.